Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 164 publications
Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults.
Journal: JAMA dermatology
Published: September 02, 2026
Correction to: Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.
Journal: American journal of clinical dermatology
Published: July 28, 2026
The dose matters: Oral tofacitinib dose escalation or switching to deuruxolitinib for recalcitrant alopecia universalis and totalis, a retrospective case series.
Journal: JAAD case reports
Published: July 06, 2026
Erosive pustular dermatosis: Rapid clearance with nintedanib.
Journal: JAAD case reports
Published: July 01, 2026
Response to Hermosa-Gelbard et al., "Switching from deuruxolitinib to baricitinib in alopecia areata: a real-world cohort of 36 patients".
Journal: Journal of the American Academy of Dermatology
Published: June 25, 2026
Hormonal associations in frontal fibrosing alopecia: A systematic review.
Journal: JAAD international
Published: June 17, 2026
Coexistence of cicatricial alopecia and alopecia areata: A case series.
Journal: JAAD case reports
Published: June 12, 2026
Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.
Journal: American journal of clinical dermatology
Published: May 28, 2026
Multisite lichen planopilaris, oral lichen planus, and vulvar lichen sclerosus treated using Janus kinase inhibitors.
Journal: International journal of women's dermatology
Published: May 08, 2026
Response to Xu, "Interpreting outcomes after switching oral Janus kinase inhibitors in alopecia areata: Comment on 'Switching between Janus kinase inhibitors for treatment of alopecia areata: A multicenter retrospective review'".
Journal: Journal of the American Academy of Dermatology
Published: May 06, 2026
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.
Journal: American journal of clinical dermatology
Published: February 20, 2026
Last Updated: 09/26/2026